Bioprocess Bags Market Outlook:
Bioprocess Bags Market size was valued at USD 4.78 Billion in 2025 and is set to exceed USD 23.57 Billion by 2035, registering over 17.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of bioprocess bags is estimated at USD 5.52 Billion.
The increasing prevalence of chronic diseases such as cancer, diabetes, autoimmune diseases, and rare genetic disorders has resulted in demand for biopharmaceuticals that require bioprocess bags. These bags facilitate sterile containment and processing of cell cultures, which is required for treating chronic conditions. Several biopharmaceutical companies are focused on expanding production capacity to meet the rising demand for bioprocessing solutions, including bioprocess bags. For instance, in March 2024, MilliporeSigma, the U.S and Canada Life Science business of Merck Group, invested around USD 325 million in its new Bioprocess Production Center in Daejeon, South Korea. The company plans to expand its production capacities in the fastest growing region, Asia Pacific, and foster deep collaboration to enhance the speed of production of new therapies.
Several companies are also forming strategic alliances to enhance the production of bioprocessing bags. For instance, in February 2022, Dow, SÜDPACK Medica, and Sartorius parented in the global COVID-19 vaccination effort by manufacturing efficient bioprocess bags. These bags are made from multilayer films to achieve better speed and quality, along with flexibility in the vaccine development and commercial manufacturing operations.
